356 related articles for article (PubMed ID: 26232650)
1. Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder.
Savitz J; Dantzer R; Meier TB; Wurfel BE; Victor TA; McIntosh SA; Ford BN; Morris HM; Bodurka J; Teague TK; Drevets WC
Psychoneuroendocrinology; 2015 Dec; 62():54-8. PubMed ID: 26232650
[TBL] [Abstract][Full Text] [Related]
2. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
[TBL] [Abstract][Full Text] [Related]
3. Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
Young KD; Drevets WC; Dantzer R; Teague TK; Bodurka J; Savitz J
Brain Behav Immun; 2016 Aug; 56():335-42. PubMed ID: 27091600
[TBL] [Abstract][Full Text] [Related]
4. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.
Savitz J; Drevets WC; Wurfel BE; Ford BN; Bellgowan PS; Victor TA; Bodurka J; Teague TK; Dantzer R
Brain Behav Immun; 2015 May; 46():55-9. PubMed ID: 25686798
[TBL] [Abstract][Full Text] [Related]
5. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.
Savitz J; Drevets WC; Smith CM; Victor TA; Wurfel BE; Bellgowan PS; Bodurka J; Teague TK; Dantzer R
Neuropsychopharmacology; 2015 Jan; 40(2):463-71. PubMed ID: 25074636
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.
Savitz J; Dantzer R; Wurfel BE; Victor TA; Ford BN; Bodurka J; Bellgowan PS; Teague TK; Drevets WC
Psychoneuroendocrinology; 2015 Feb; 52():200-11. PubMed ID: 25486577
[TBL] [Abstract][Full Text] [Related]
7. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
[TBL] [Abstract][Full Text] [Related]
8. Serum kynurenic acid is reduced in affective psychosis.
Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
[TBL] [Abstract][Full Text] [Related]
9. C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.
Zheng H; Teague TK; Yeh FC; Burrows K; Figueroa-Hall LK; Aupperle RL; Khalsa SS; Paulus MP; Savitz J
Brain Behav Immun; 2022 Oct; 105():180-189. PubMed ID: 35853557
[TBL] [Abstract][Full Text] [Related]
10. Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression.
Meier TB; Drevets WC; Teague TK; Wurfel BE; Mueller SC; Bodurka J; Dantzer R; Savitz J
Brain Behav Immun; 2018 Jan; 67():59-64. PubMed ID: 28867283
[TBL] [Abstract][Full Text] [Related]
11. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Ning Y
Psychoneuroendocrinology; 2019 Mar; 101():72-79. PubMed ID: 30419374
[TBL] [Abstract][Full Text] [Related]
12. Real-time fMRI neurofeedback amygdala training may influence kynurenine pathway metabolism in major depressive disorder.
Tsuchiyagaito A; Smith JL; El-Sabbagh N; Zotev V; Misaki M; Al Zoubi O; Kent Teague T; Paulus MP; Bodurka J; Savitz J
Neuroimage Clin; 2021; 29():102559. PubMed ID: 33516062
[TBL] [Abstract][Full Text] [Related]
13. Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease.
Pawlak K; Brzosko S; Mysliwiec M; Pawlak D
Atherosclerosis; 2009 Jun; 204(2):561-6. PubMed ID: 19027117
[TBL] [Abstract][Full Text] [Related]
14. Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers.
Dahl J; Andreassen OA; Verkerk R; Malt UF; Sandvik L; Brundin L; Ormstad H
Psychoneuroendocrinology; 2015 Jun; 56():12-22. PubMed ID: 25770856
[TBL] [Abstract][Full Text] [Related]
15. Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients.
Schwieler L; Samuelsson M; Frye MA; Bhat M; Schuppe-Koistinen I; Jungholm O; Johansson AG; Landén M; Sellgren CM; Erhardt S
J Neuroinflammation; 2016 Feb; 13(1):51. PubMed ID: 26925576
[TBL] [Abstract][Full Text] [Related]
16. Sleep disturbance and kynurenine metabolism in depression.
Cho HJ; Savitz J; Dantzer R; Teague TK; Drevets WC; Irwin MR
J Psychosom Res; 2017 Aug; 99():1-7. PubMed ID: 28712413
[TBL] [Abstract][Full Text] [Related]
17. Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid.
Savitz J; Ford BN; Yeh HW; Akeman E; Cosgrove K; Clausen AN; Martell C; Kirlic N; Santiago J; Teague TK; Irwin MR; Paulus MP; Aupperle RL
Psychol Med; 2022 Oct; 52(13):2500-2509. PubMed ID: 33234171
[TBL] [Abstract][Full Text] [Related]
18. The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.
Ou W; Chen Y; Ju Y; Ma M; Qin Y; Bi Y; Liao M; Liu B; Liu J; Zhang Y; Li L
J Affect Disord; 2023 Oct; 339():624-632. PubMed ID: 37467793
[TBL] [Abstract][Full Text] [Related]
19. Peripheral and central kynurenine pathway abnormalities in major depression.
Paul ER; Schwieler L; Erhardt S; Boda S; Trepci A; Kämpe R; Asratian A; Holm L; Yngve A; Dantzer R; Heilig M; Hamilton JP; Samuelsson M
Brain Behav Immun; 2022 Mar; 101():136-145. PubMed ID: 34999196
[TBL] [Abstract][Full Text] [Related]
20. Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders.
Savitz J
Curr Top Behav Neurosci; 2017; 31():249-267. PubMed ID: 27221627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
